Skip to content

Susannah E Murphy

4 papers in the library · 3 citations · publishing 2025-2026

Papers

Sort Most recent Most cited

Ketamine attenuates habenula activity in response to aversive outcomes during Pavlovian learning

bioRxiv (Cold Spring Harbor Laboratory) February 10, 2026 Erdem Pulcu, Sara Costi, Pilar Artiach-Hortelano et al.

Abstract Ketamine is an NMDA receptor antagonist with rapid-antidepressant properties when administered at a sub-anesthetic dose. Preclinical models indicate that a direct injection of ketamine into lateral habenula (Hb), a small midbrain structure with an evolutionarily preserved role in aversive learning across mammals, can rapidly relieve depression-like behavior. However, there is limited...

Nitrous oxide for the treatment of depression: a systematic review and meta-analysis.

EBioMedicine December 1, 2025 Kiranpreet Gill, Angharad N De Cates, Chantelle Wiseman et al.

Depression remains a global public health challenge, prompting interest in translational targets which allow for more effective and rapidly acting interventions. Nitrous oxide (N2O), an N-methyl-d-aspartate receptor antagonist, has demonstrated potential as a rapid-acting antidepressant. This study synthesised existing data on the efficacy and safety of N2O in depressive disorders. We...

The cognitive neuroscience of ketamine in major depression.

Brain : a journal of neurology June 30, 2025 Sara Costi, Chloe Wigg, Erdem Pulcu et al. 3 citations

Ketamine's potential as a rapid-acting antidepressant was first identified in 2000, despite its long-standing use as an anesthetic agent. Clinically, ketamine alleviates depressive symptoms, including the difficult to treat symptom of anhedonia, within hours, with the effects of a single dose lasting for days. Since then, research has focused on uncovering the mechanisms underlying its rapid...

Examining memory reconsolidation as a mechanism of nitrous oxide's antidepressant action.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology March 1, 2025 Ella Williams, Ursule Taujanskaite, Sunjeev K. Kamboj et al.

There is an ongoing need to identify novel pharmacological agents for the effective treatment of depression. One emerging candidate, which has demonstrated rapid-acting antidepressant effects in treatment-resistant groups, is nitrous oxide (N2O)-a gas commonly used for sedation and pain management in clinical settings and with a range of pharmacological effects, including antagonism of NMDA...